Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-1

PD-1

Brief Information

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1,CD279,hPD-1,PDCD1,Programmed Cell Death 1,Systemic Lupus Erythematosus Susceptibility 2,Protein PD-1,PD1,Programmed Cell Death 1 Protein,CD279 Antigen,HPD-L,HSLE1,SLEB2,PD-1,Programmed Cell Death 1 Receptor
Number of Launched Drugs:11
Number of Drugs in Clinical Trials:110
Lastest Research Phase:Phase 2 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BLL202202 broad cancer Ready for CMC development License-out or co-development
BBS21008 Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer. Pre-clinical, CMC developing; Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.)

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SCJUR-STF064 Human Human PD-1 (Luc) Jurkat Reporter Cell Development Service
PD1-C52H5 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H5-structure
PD1-C52H5-sds
RAB-P002 Human Human Anti-PD-1 Antibody IgG Titer Serologic ELISA Assay Kit
PD1-C52E5 Canine Biotinylated Canine PD-1 / PDCD1 Protein, His,Avitag™
PD1-C52E5-structure
PD1-C52E5-sds
EP-120 Human PD-1 [Biotinylated] : PD-L2 Inhibitor Screening ELISA Kit
EP-130 Human PD-1: PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit
PD1-H5256 Human Human PD-1 / PDCD1 Protein, Fc,His Tag
PD1-H5256-structure
PD1-H5256-sds
PD1-H52H2 Human Human PD-1 Protein, His tag (Nanoparticle)
PD1-H52H2-sds
PD1-C52H9 Canine Canine PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H9-structure
PD1-C52H9-sds
PD1-H82A4 Human Biotinylated Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A4-structure
PD1-H82A4-sds
PD1-R52H3 Rhesus macaque Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H3-structure
PD1-R52H3-sds
PD1-H52H6 Human Human PD-1 / PDCD1 Full Length Protein, His Tag
PD1-H52H6-structure
PD1-H52H6-sds
PD1-H82F4 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F4-structure
PD1-H82F4-sds
PD1-C82E6 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, His,Avitag™
PD1-C82E6-structure
PD1-C82E6-sds
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc,His Tag (recommended for neutralizing assay)
PD1-HP2F2-structure
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H5255-structure
PD1-H5255-sds
PD1-H5255-hplc
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)
PD1-H522a-structure
PD1-H522a-sds
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
PD1-H5259-structure
PD1-H5259-sds
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-H82F1-structure
PD1-H82F1-sds
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-RB5251-structure
PD1-RB5251-sds
PD1-M52A4 Mouse Mouse PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag
PD1-M52A4-structure
PD1-M52A4-sds
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-R52H2-structure
PD1-R52H2-sds
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)
PD1-H82E4-structure
PD1-H82E4-sds
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H0-structure
PD1-R52H0-sds
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS Verified)
PD1-M82F4-structure
PD1-M82F4-sds
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-R5253-structure
PD1-R5253-sds
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259-structure
PD1-M5259-sds
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Strep Tag (MALS verified)
PD1-H5284-structure
PD1-H5284-sds
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-M5228-structure
PD1-M5228-sds
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag (MALS verified)
PD1-C5254-structure
PD1-C5254-sds
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (MALS Verified)
PD1-H5257-structure
PD1-H5257-sds
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (MALS Verified)
PD1-H5221-structure
PD1-H5221-sds

Part of Bioactivity data

SCJUR-STF064-Cell-based assay
PD-1 FACS

Expression analysis of human PD-1 on Human PD-1 (Luc) Jurkat Reporter Cell by FACS.
Human PD-1 (Luc) Jurkat Reporter Cell or negative control cell were stained with FITC-labeled anti-human PD1 antibody.

Protocol
PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μL stock solution per million cells (QC tested).

Protocol
PD1-R52H0-SPR
Human_FcRn_Heterodimer_Protein_SPR

Rabbit PD-L1, His Tag (Cat. No. PDL-R52H6) immobilized on CM5 Chip can bind Rabbit PD-1, His Tag (Cat. No. PD1-R52H0) with an affinity constant of 3.87 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
PD1-M5259-SPR
PD-1 SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

PDCD1,PD1,CD279,SLEB2

Background

How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Prolgolimab BCD-100 Approved Biocad Forteca Russian Federation Melanoma Biocad 2020-04-01 Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG United States Melanoma Bristol-Myers Squibb Company 2022-03-18 Solid tumours; Melanoma Details
Penpulimab AK-105 Approved Zhongshan Akeso Biopharma Co Ltd 安尼可 Mainland China Hodgkin Disease Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd 2021-08-03 Solid tumours; Liver Neoplasms; Hodgkin Disease; Neoplasms; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Cadonilimab AK-104 Approved Zhongshan Akeso Biopharma Co Ltd 开坦尼 Mainland China Uterine Cervical Neoplasms Kangfang Pharmaceutical Co Ltd 2022-06-29 Microsatellite Instability; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; DNA Repair-Deficiency Disorders; Colorectal Neoplasms; Urologic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Lymphoma, T-Cell, Peripheral Details
Toripalimab TAB-001; JS-001; SO-001; JS-001sc Approved Shanghai Junshi Biosciences Co Ltd, Suzhou Union Biopharm Biosciences Co Ltd 拓益 Mainland China Esophageal Squamous Cell Carcinoma Shanghai Junshi Biosciences Co Ltd 2018-12-17 Esophageal Squamous Cell Carcinoma; Neuroendocrine Tumors; Rejection of organ transplantation; Liposarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Urologic Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Urinary Bladder Neoplasms; Lymphoma; Epstein-Barr Virus Infections; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Biliary Tract Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pain; Solid tumours; Rejection of liver transplantation; Anus Neoplasms; Hypopharyngeal Neoplasms; Neoplasms; Colonic Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Neoplasms; Nasopharyngeal Diseases Details
Pucotenlimab AK-103; HX-008 Approved Zhongshan Akeso Biopharma Co Ltd, Taizhou Hanzhong Biomedical Co Ltd, Hanx Biopharmaceutical Co Ltd 普佑恒 Mainland China Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer Lepu Biotech Co Ltd 2022-07-19 Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Mismatch Repair Deficient Cancer; Triple Negative Breast Neoplasms; Thyroid Carcinoma, Anaplastic; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms Details
Zimberelimab AB-122; GLS-010; WBP-3055 Approved Harbin Gloria Pharmaceuticals Co Ltd, Wuxi Biologics (Shanghai) Co Ltd 誉妥 Mainland China Hodgkin Disease Guangzhou Yuheng Biotechnology Co Ltd 2021-08-25 Mouth Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Prostatic Neoplasms, Castration-Resistant; Laryngeal Neoplasms; Pharyngeal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Merkel Cell; Solid tumours; Neoplasms; Hodgkin Disease; Triple Negative Breast Neoplasms; Glioblastoma; Hypopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Urinary Bladder Neoplasms Details
Sintilimab IBI-308 Approved Innovent Biologics(Suzhou) Co Ltd Tyvyt, 达伯舒 Mainland China Stomach Neoplasms Innovent Biologics(Suzhou) Co Ltd 2018-12-24 Mouth Neoplasms; Microsatellite Instability; Breast Neoplasms; Lymphoma, Extranodal NK-T-Cell; Osteosarcoma; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Carcinoma, Small Cell; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Precancerous Conditions; Melanoma; Pancreatic Neoplasms; Biliary Tract Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Thoracic Neoplasms; Ovarian Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Neoplasms; Respiratory Tract Diseases; Adenocarcinoma of Lung; Neuroendocrine Tumors; Lung Diseases Details
Dostarlimab WBP-285; TSR-042; ANB-011 Approved Anaptysbio Inc JEMPERLI United States Solid tumours Glaxosmithkline Llc 2021-04-21 Ovarian Neoplasms; Solid tumours; Neoplasms; Colonic Neoplasms; Gestational Trophoblastic Disease; Sarcoma, Clear Cell; Colorectal Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
Camrelizumab SHR-1210; INCSHR-1210; HR-301210 Approved Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd AiRuiKa, 艾瑞卡, 艾立妥 Mainland China Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Suzhou Suncadia Biopharmaceuticals Co Ltd 2019-05-29 Lung Neoplasms; Nasopharyngeal Carcinoma; Sarcoma; Respiratory Tract Neoplasms; Cholangiocarcinoma; Lymphoma, Extranodal NK-T-Cell; Breast Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Thyroid Neoplasms; Lymphoma; Lung Diseases; Endometrial Neoplasms; Carcinoma, Squamous Cell; Paranasal Sinus Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms; Melanoma; Uterine Cervical Neoplasms; Esophageal Diseases; Hodgkin Disease; Liver Neoplasms; Intestinal Neoplasms; Carcinoma, Bronchogenic; Ovarian Neoplasms; Hemorrhagic Fever, Ebola; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Bronchial Neoplasms; Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Nasopharyngeal N Details
Tislelizumab BGB-A317; VDT-482 Approved Beigene Ltd 百泽安 Mainland China Nasopharyngeal Carcinoma Beigene Guangzhou Biologics Manufacturing Co Ltd 2019-12-26 Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Extranodal NK-T-Cell; Breast Neoplasms; Nasopharyngeal Carcinoma; Microsatellite Instability; Cholangiocarcinoma; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Esophageal Squamous Cell Carcinoma; Lymphoma, Follicular; Esophageal adenocarcinoma; Carcinoma, Squamous Cell; Lung Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Head and Neck Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Hodgkin Disease; Carcinoma, Transitional Cell; Neoplasms; Nasopharyngeal Neop Details
Serplulimab HLX-10 Approved Shanghai Henlius Biotech Co Ltd 汉斯状 Mainland China Microsatellite instability-high cancer Shanghai Henlius Biopharmaceuticals Co Ltd 2022-03-22 Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Carcinoma, Adenosquamous; Microsatellite Instability; Microsatellite instability-high cancer; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Liver Neoplasms; Solid tumours Details
Nivolumab MDX-1106; ONO-4538; ono-0123; BMS-936558; BMS-936558-01 Approved Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd Opdivo, 欧狄沃 Japan Carcinoma, Transitional Cell Ono Pharmaceutical Co Ltd 2014-07-04 Chondrosarcoma; Head and Neck Neoplasms; Liver Neoplasms; Rhabdomyosarcoma; Solid tumours; Leiomyosarcoma; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Ependymoma; Skin Melanoma; Hematologic Neoplasms; Acquired Immunodeficiency Syndrome; Tobacco Smoking; Ovarian Neoplasms; Leukemia; Medulloblastoma; Craniopharyngioma; Kidney Neoplasms; Biliary Tract Neoplasms; Fibrosarcoma; HIV Infections; Esophageal Neoplasms; Irritable Bowel Syndrome; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thoracic Neoplasms; Rectal Neoplasms; Giant Cell Arteritis; Leukoplakia, Oral; Mismatch Repair Deficient Cancer; Hepatitis B, Chronic; Carcinoma; Histiocytoma, Malignant Fibrous; Lymphadenopathy; Leukemia, Lymphoid; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Fibrolamellar hepatocellular carcinoma; Colonic Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Adrenal Cortex Neoplasms; Glioblastoma; Arthritis, Rheumatoid; Skin Neoplasms; Pancre Details
Cemiplimab REGN-2810; SAR-439684 Approved Regeneron Pharmaceuticals Inc Libtayo United States Carcinoma, Non-Small-Cell Lung Regeneron Pharmaceuticals Inc 2018-09-28 Hepatitis B; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Fallopian Tube Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Diffuse Intrinsic Pontine Glioma; Sarcoma; Prostatic Neoplasms; Solid tumours; Central Nervous System Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Neoplasms; Glioblastoma; Hodgkin Disease; Skin Neoplasms; Carcinoma, Merkel Cell; Hemangiosarcoma; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Ovarian Neoplasms; HIV Infections Details
Pembrolizumab SCH-900475; h409A11; MK-3475 Approved Merck & Co Inc 可瑞达, Keytruda EU Uterine Cervical Neoplasms; Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer Merck Sharp & Dohme Bv 2014-09-04 Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Liver Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Kidney Neoplasms; Endocrine Gland Neoplasms; Solitary Fibrous Tumor, Pleural; Skin Melanoma; Acquired Immunodeficiency Syndrome; Lymphoma, B-Cell, Marginal Zone; Biliary Tract Neoplasms; Erythema; Neoplasm, Residual; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Bone metastases; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Bronchial Neoplasms; Spinal Cord Neoplasms; Thoracic Neoplasms; Carcinoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Anus Neoplasms; Vaginal Diseases; Carcinoid Tumor; Mismatch Repair Deficient Cancer; Polycythemia Vera; Cystadenocarcinoma, Serous; Genital Neoplasms, Male; Viremia; Vaginitis; Hodgkin Disease; Carcinoma, Ovarian Epithelial; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neuroectodermal Tumors; Glioblastoma; Colonic Neop Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
RB-0004 RB-0004 Phase 1 Clinical Reyoung Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase 2 Clinical Anhui Korton Biological Technology Co Ltd Esophageal Neoplasms Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
89Zr-N-sucDf-pembrolizumab Phase 1 Clinical Merck & Co Inc, Umcg The University Medical Center Groningen Carcinoma, Non-Small-Cell Lung; Melanoma Details
BA1104 LY-01015; BA-1104 Phase 1 Clinical Luye Pharma Group Ltd Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase 2 Clinical Nanjing Medical University Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma Details
STW204 STW-204; AI025; AI-025 Phase 1 Clinical Suzhou Stainwei Biotech Inc Solid tumours; Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) Phase 1 Clinical Shanxi Weiqidaguangming Pharmaceutical Co Ltd Solid tumours Details
INSIX RA (Indus Biotech) Clinical Indus Biotech Pvt Ltd Arthritis, Rheumatoid; Inflammation Details
Treprilimab Clinical Sun Yat-Sen University Oropharyngeal Neoplasms Details
ABBV-1882 ABBV-1882 Phase 1 Clinical Abbvie Inc HIV Infections Details
Pembrolizumab biosimilar (biocad) BCD-201 Phase 1 Clinical Biocad Solid tumours Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) Bis-5 Phase 1 Clinical Neoplasms Details
Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) Phase 2 Clinical Carcinoma, Ovarian Epithelial; Bile Duct Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
PH-762 PH-762 Phase 1 Clinical Breast Neoplasms; Melanoma Details
SSGJ-706 SSGJ-706 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
HerinCAR-PD1 Phase 2 Clinical Ningbo Cancer Hospital Solid tumours Details
EBV-specific TCR-T cell with anti-PD1 auto-secreted element Phase 2 Clinical Tcrcure Biopharma Ltd Squamous Cell Carcinoma of Head and Neck Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
SSGJ-705 SSGJ-705 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
PE0105 PE-0105 Phase 1 Clinical Shanghai Yunyi Health Technology Development Co Ltd Neoplasms Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) Phase 1 Clinical Dongguan City Hec Biological Medicine Res And Development Co Ltd Stomach Neoplasms; Esophageal adenocarcinoma Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
MEDI-0680 AMP-514; MEDI-0680 Medimmune Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase 2 Clinical Chengdu Medgencell, West China Hospital Of Sichuan University Lung Neoplasms; Melanoma Details
MW-11 MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Breast Neoplasms Details
Acrixolimab YBL-006; YBL 006 Phase 1 Clinical Y-biologics Inc Solid tumours Details
IBI-319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
GNR-051 GNR-051 Generium Pharmaceuticals Details
PF-07209960 PF-07209960 Phase 1 Clinical Pfizer Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung Details
CD-200-AR-L CD-200-AR-L; hP-1-A-8 Phase 1 Clinical University Of Minnesota Glioblastoma Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
IMU-201 IMU-201 Imugene Details
JS-201 JS-201 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
LBL-015 LBL-015 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours Details
SHR-1901 SHR-1901 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd Neoplasms Details
SSI-361 LVGN-3616; SSI-361 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Neoplasms Details
CA-170 CA-170; AUPM-170 Aurigene Details
Latikafusp AMG-256 Amgen Inc Details
TQB-2868 TQB-2868 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
Rosnilimab ANB-030 Anaptysbio Inc Alopecia Areata Details
MK-3475A MK-3475A Merck Sharp & Dohme Corp Details
Peramprizumab Phase 2 Clinical Sun Yat-Sen University Nasopharyngeal Carcinoma Details
Sym-024 Sym-024; S-95024 Symphogen A/S Details
BI-1387446 C.H. Boehringer Sohn Ag & Co. Kg Details
AZD-7789 AZD-7789 Phase 2 Clinical AstraZeneca Ag Carcinoma, Non-Small-Cell Lung Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Neoplasm Metastasis Details
BCD-217 BCD-217 Biocad Details
BAT-1308 BAT-1308 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
CMAB-819 CMAB8-19 Phase 1 Clinical Sinomab Bioscience Ltd Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Sym-021 Sym-021 Symphogen Details
Izuralimab XmAb-23104; XmAb-104 Xencor Details
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) Xinqiao Hospital, Army Medical University Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) SG-001; SYSA1802 Phase 2 Clinical Hangzhou Sumgen Biotechnology Co Ltd Triple Negative Breast Neoplasms; Neoplasms; Mesothelioma; Uterine Cervical Neoplasms Details
Fidasimtamab IBI-315 Phase 1 Clinical Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
Nofazinlimab CS-1003 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Lymphoma; Carcinoma, Hepatocellular Details
QL1604 QL1604; QL-1604 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
ONCR-177 ONCR-177 Oncorus Details
Programmed cell death 1 antibody (Sun Yat-sen University) Sun Yat-Sen University Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) 609-A; SSGJ-609A; SSGJ-609-A Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Sarcoma Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
Pimivalimab JTX-4014 Jounce Therapeutics Details
Pidilizumab MDV-9300; CT-011 Phase 2 Clinical Curetech Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic Details
Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) Phase 1 Clinical Sun Yat-Sen University Nasopharyngeal Carcinoma Details
Peresolimab LY-3462817 Phase 2 Clinical Eli Lilly And Company Arthritis, Rheumatoid; Psoriasis Details
Sasanlimab PF-06801591; PF-6801591; RN-888 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Solid tumours; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
Cetrelimab JNJ-63723283; JNJ-3283 Phase 3 Clinical Johnson & Johnson Hepatitis B, Chronic; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell Details
IAP-0971 IAP-0971 Phase 2 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours; Neoplasms Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Carcinoma, Non-Small-Cell Lung Details
Finotonlimab SCT-I10A Phase 3 Clinical SinoCelltech Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
ZG-005 ZG-005 Phase 2 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
Mavezelimab/Pembrolizumab MK-4280A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms Details
Ezabenlimab BI-754091 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis Details
TC-510 TC-510 Phase 2 Clinical Tcr2 Therapeutics Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Colorectal Neoplasms; Adenocarcinoma Details
Zeluvalimab AMG-404 Phase 2 Clinical Amgen Inc Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms Details
Recombinant human PD-1 antibody herpes simplex virus Phase 1 Clinical Yangsheng Tang Co Ltd, Xiamen University Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
Budigalimab ABBV-181 Phase 2 Clinical Abbvie Inc Solid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HX-009 HX-009 Phase 2 Clinical Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma Details
Rituximab/Paclitaxel AR-160 Phase 2 Clinical Mayo Clinic Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase 2 Clinical Anhui Anke Biotechnology (Group) Co Ltd Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms Details
TY-101 TY-101; TY101 Phase 2 Clinical Tayu Huaxia Biotech Medical Group Co Ltd Solid tumours; Lymphoma Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Solid tumours; Carcinoma, Renal Cell Details
NIR-178 PBF-509; NIR-178 Phase 2 Clinical Palobiofarma Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase 2 Clinical Radboud University Nijmegen Hematologic Neoplasms; Colorectal Neoplasms Details
ONO-4685 ONO-4685 Phase 1 Clinical Merus Psoriasis; Lymphoma, T-Cell Details
CC-90006 C-90006; CC-90006 Phase 1 Clinical Anaptysbio Inc Autoimmune Diseases; Psoriasis Details
T3011 MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV Phase 2 Clinical Immvira Co Ltd Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Reozalimab IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Vudalimab XmAb-20717; XmAb-717 Phase 2 Clinical Xencor Vulvar Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Carcinoma, Squamous Cell; Astrocytoma; Colorectal Neoplasms; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Prostatic Neoplasms; Solid tumours; Breast Neoplasms; Nasopharyngeal Carcinoma; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Biliary Tract Neoplasms Details
Pembrolizumab/Quavonlimab MK-1308A Phase 3 Clinical Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Hematologic Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Lorigerlimab MGD-019; AEX1344 Phase 2 Clinical Macrogenics Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Rulonilimab F-520 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Solid tumours; Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neurolymphomatosis; Lymphoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
LZM-009 LZM-009 Phase 2 Clinical Livzon(Group) Pharmaceutical Factory Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung Details
Ivonescimab AK-112 Phase 3 Clinical Zhongshan Akeso Biopharma Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Retifanlimab INCMGA-0012; INCMGA-00012; MGA-012 Phase 3 Clinical Macrogenics Esophageal adenocarcinoma; Prostatic Neoplasms; Sarcoma; Lymphoma, Follicular; Breast Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Glioma; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Melanoma; Gastrointestinal Neoplasms; Anus Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Merkel Cell; Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Oligodendroglioma; Liposarcoma Details
Spartalizumab PDR-001 Phase 3 Clinical Novartis Pharma Ag Lymphoma; Chordoma; Urinary Bladder Neoplasms; Uveal melanoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Primary Myelofibrosis; Gastrointestinal Stromal Tumors; Bone Marrow Diseases; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Uterine Neoplasms; Esophageal adenocarcinoma; Thyroid Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Endometrioid; Lymphoma, Large B-Cell, Diffuse; Ovarian Neoplasms; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Liver Neoplasms; Solid tumours; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IBI-363 IBI-363 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms; Lymphoma Details
Iparomlimab/Tuvonralimab QL-1706; PSB-205; PBS-103/PBS-105 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
RO-7121661 RG-7769; RO-7121661 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
SI-B003 SI-B003 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap